• Home
  • News
  • Press Releases

SomaGenics awarded NIH funding to develop NGS Single-Cell analysis of small RNAs

Santa Cruz, CA, October 2017- SomaGenics announced the receipt of a Phase I SBIR grant from NIH to develop RealSeq®-SC (Single Cell), expected to be the first commercially available library preparation kit for profiling small RNAs (including microRNAs) from single cells using NGS methods. NIH's recent Single Cell Analysis Program highlights the need to accelerate development of approaches to analyze the heterogeneity of cell populations.

Continue Reading

SomaGenics awarded NIH funding to develop novel cell-free-DNA liquid biopsy platform

Santa Cruz, CA, May 2017- SomaGenics announced the receipt of a Phase I SBIR grant from the National Human Genome Research Institute to support extension of its RealSeq® platform to the sequence analysis of highly fragmented cell-free DNA (cf-DNA).  The original version of this platform technology, RealSeq®-AC, allows construction of unbiased libraries for next-generation sequencing of small RNAs (such as microRNAs) and short fragments of large RNAs.  The new grant, entitled Advanced method for preparing cell-free (cf) DNA sequencing libraries, will support development of the DNA version, called RealSeq®-DC, and demonstration of its expected superiority over currently available methods for fragmented DNA-seq library preparation.

Continue Reading

SomaGenics Presents RNAi Therapeutic Program

Santa Cruz, CA, May, 2017 – SomaGenics’ President and CEO, Brian Johnston, Ph.D., recently presented an invited seminar, “Treating chronic diabetic wounds: A small RNA approach,” to the Institute for RNA Medicine of Beth Israel Deaconess Medical Center, just renamed the Harvard Medical School Initiative on RNA Medicine (IRM).  SomaGenics’ novel synthetic short hairpin RNA (sshRNA®) platform has been used to develop therapeutic candidates for chronic diabetic wounds as well as treatments for hepatitis delta virus.  Dr. Johnson was invited to serve on the IRM Business Advisory Board.  “I am looking forward to the opportunity to work with the IRM’s scientists and stakeholders and hope to contribute to advancing RNA-based treatments across many therapeutic areas.”

Continue Reading